This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Optimal Dosing With Risperidone: Updated Recommendations

Richard Williams

Published: April 1, 2001

Article Abstract

Background: Drug dosages utilized duringcontrolled clinical trials are not always optimal for patientsencountered in day-to-day practice. The original trials ofrisperidone, a novel antipsychotic, suggested that an initialtarget dose of 6 mg/day was appropriate, but these trials werenecessarily conducted among patients who were chronicallyimpaired, hospitalized, and often partly drug resistant.

Data Sources: Relevant data relating to thedosage of risperidone identified through an online (MEDLINE)search using the keywords risperidone, schizophrenia,schizoaffective disorder, dementia, bipolardisorder, and dose were supplemented by a review ofinternational and U.S. Congress abstracts in which the dose ofrisperidone was specifically described.

Conclusion: On the basis of naturalisticstudies, clinical audit, phase 4 trials, positron emissiontomography data, and 5 years of clinical experience, thecurrently recommended target dose of risperidone is 4 mg/day formost patients, with less-rapid titration than previouslyrecommended. Moreover, a lower dose than this and slowertitration may be appropriate for elderly patients, youngpatients, and first-episode patients.

Volume: 62

Quick Links: Dementia , Neurologic and Neurocognitive

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...